BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin-carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 2010;65:379-82. [DOI: 10.1093/jac/dkp492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Soriano V, de Mendoza C, Fernández-montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. Annals of Medicine 2014;46:290-6. [DOI: 10.3109/07853890.2014.899103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
2 Schirmer P, Winters M, Holodniy M. HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. Journal of Clinical Virology 2011;52:261-4. [DOI: 10.1016/j.jcv.2011.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
3 Taramasso L, Caligiuri P, Di Biagio A, Bruzzone B, Rosso R, Icardi G, Viscoli C. Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. J Med Virol 2011;83:1905-8. [PMID: 21915864 DOI: 10.1002/jmv.22192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013;17:489-501. [PMID: 23905818 DOI: 10.1016/j.cld.2013.05.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
6 Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol 2011;2011:405390. [PMID: 21991507 DOI: 10.5402/2011/405390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
8 Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. Microorganisms 2021;9:396. [PMID: 33671934 DOI: 10.3390/microorganisms9020396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]